Matches in SemOpenAlex for { <https://semopenalex.org/work/W3128955181> ?p ?o ?g. }
Showing items 1 to 77 of
77
with 100 items per page.
- W3128955181 abstract "Abstract Background Clinical studies have suggested that PD-1 inhibitor is useful in the management of advanced Esophageal Cancer. However, the efficacy and safety of Anti-PD-1 inhibitor for the treatment of advanced Esophageal Cancer is inconclusive. Thus, we conducted a meta-analysis aiming to comprehensively explore the effectiveness and safety of the therapeutic effects of PD-1 inhibitors on patients with advanced esophageal cancer. Methods & Materials: The PubMed (since its inception), Cochrane library (since its inception), EMBASE (since its inception),and ClinicalTrials.gov (since its inception) were searched till 1st December 2020 for the randomized controlled trials (RCTs) that evaluated the effectiveness and safety of PD-1 inhibitors for patients with esophageal cancer. Two investigators independently performed study selection, data extraction and assessment of the methodological quality. RevMan 5.3 was applied statistical analysis. Results Three RCTs were included for this meta-analysis ,with a total of 1477 patients. Compared with chemotherapy, PD-1 inhibitors had superior objective response rates(Odds ratio(OR) = 14.96, 95% confidence interval (CI):0.47,476.97; P = 0.13). PD-1 inhibitors group had better overall survival compared to chemotherapy group(Hazard ratio(HR):0.80,95% CI:0.70,0.91,P = 0.0007) .The progression-free survival (HR:0.94,95% CI:0.71,1.26,P = 0.69) were similar between the two groups. The grade 3 or more adverse events rate were lower in the PD-1 inhibitors group as compared to those of chemotherapy group(OR:0.25,95% CI:0.13,0.46,P < 0.0001). Conclusions Our study indicated that PD-1 inhibitors are efficacious and safe for the management of EC refractory or intolerant to previous chemotherapy." @default.
- W3128955181 created "2021-02-15" @default.
- W3128955181 creator A5001960617 @default.
- W3128955181 creator A5044942960 @default.
- W3128955181 creator A5059040478 @default.
- W3128955181 creator A5065166722 @default.
- W3128955181 creator A5072950121 @default.
- W3128955181 creator A5086533374 @default.
- W3128955181 date "2021-02-05" @default.
- W3128955181 modified "2023-10-18" @default.
- W3128955181 title "Anti-PD-1 Inhibitor for the Treatment of Esophageal Cancer Refractory or Intolerant to Previous Chemotherapy: A Meta-Analysis of Randomized Controlled Trials" @default.
- W3128955181 doi "https://doi.org/10.21203/rs.3.rs-156736/v1" @default.
- W3128955181 hasPublicationYear "2021" @default.
- W3128955181 type Work @default.
- W3128955181 sameAs 3128955181 @default.
- W3128955181 citedByCount "0" @default.
- W3128955181 crossrefType "posted-content" @default.
- W3128955181 hasAuthorship W3128955181A5001960617 @default.
- W3128955181 hasAuthorship W3128955181A5044942960 @default.
- W3128955181 hasAuthorship W3128955181A5059040478 @default.
- W3128955181 hasAuthorship W3128955181A5065166722 @default.
- W3128955181 hasAuthorship W3128955181A5072950121 @default.
- W3128955181 hasAuthorship W3128955181A5086533374 @default.
- W3128955181 hasBestOaLocation W31289551811 @default.
- W3128955181 hasConcept C121332964 @default.
- W3128955181 hasConcept C121608353 @default.
- W3128955181 hasConcept C126322002 @default.
- W3128955181 hasConcept C141071460 @default.
- W3128955181 hasConcept C142424586 @default.
- W3128955181 hasConcept C143998085 @default.
- W3128955181 hasConcept C156957248 @default.
- W3128955181 hasConcept C168563851 @default.
- W3128955181 hasConcept C197934379 @default.
- W3128955181 hasConcept C207103383 @default.
- W3128955181 hasConcept C2776478404 @default.
- W3128955181 hasConcept C2776694085 @default.
- W3128955181 hasConcept C2779742542 @default.
- W3128955181 hasConcept C44249647 @default.
- W3128955181 hasConcept C71924100 @default.
- W3128955181 hasConcept C87355193 @default.
- W3128955181 hasConcept C90924648 @default.
- W3128955181 hasConcept C95190672 @default.
- W3128955181 hasConceptScore W3128955181C121332964 @default.
- W3128955181 hasConceptScore W3128955181C121608353 @default.
- W3128955181 hasConceptScore W3128955181C126322002 @default.
- W3128955181 hasConceptScore W3128955181C141071460 @default.
- W3128955181 hasConceptScore W3128955181C142424586 @default.
- W3128955181 hasConceptScore W3128955181C143998085 @default.
- W3128955181 hasConceptScore W3128955181C156957248 @default.
- W3128955181 hasConceptScore W3128955181C168563851 @default.
- W3128955181 hasConceptScore W3128955181C197934379 @default.
- W3128955181 hasConceptScore W3128955181C207103383 @default.
- W3128955181 hasConceptScore W3128955181C2776478404 @default.
- W3128955181 hasConceptScore W3128955181C2776694085 @default.
- W3128955181 hasConceptScore W3128955181C2779742542 @default.
- W3128955181 hasConceptScore W3128955181C44249647 @default.
- W3128955181 hasConceptScore W3128955181C71924100 @default.
- W3128955181 hasConceptScore W3128955181C87355193 @default.
- W3128955181 hasConceptScore W3128955181C90924648 @default.
- W3128955181 hasConceptScore W3128955181C95190672 @default.
- W3128955181 hasLocation W31289551811 @default.
- W3128955181 hasOpenAccess W3128955181 @default.
- W3128955181 hasPrimaryLocation W31289551811 @default.
- W3128955181 hasRelatedWork W1900595920 @default.
- W3128955181 hasRelatedWork W1984235851 @default.
- W3128955181 hasRelatedWork W2067140660 @default.
- W3128955181 hasRelatedWork W2554756453 @default.
- W3128955181 hasRelatedWork W2889691785 @default.
- W3128955181 hasRelatedWork W3124218749 @default.
- W3128955181 hasRelatedWork W3154231528 @default.
- W3128955181 hasRelatedWork W4291824836 @default.
- W3128955181 hasRelatedWork W4292182750 @default.
- W3128955181 hasRelatedWork W4317438754 @default.
- W3128955181 isParatext "false" @default.
- W3128955181 isRetracted "false" @default.
- W3128955181 magId "3128955181" @default.
- W3128955181 workType "article" @default.